Isidora Savorgiannakis
Medical · Florham Park, NJNPI 1134766025
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.6% of the total across 285 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 38 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $2,762 and has fallen 53.2% since, to $1,293 in 2023. Among medical clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 285 payments — averaging $20.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$705
- Boehringer Ingelheim$579
- Biohaven Pharmaceutical Holding Company Ltd.$470
- AbbVie$424
- GSK$381
- Intra-sana Laboratories$372
- plus $3K from 32 others
What the payments were for
- Food & beverage$5,73797%
- Gifts$2003%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 39 | $705 |
| Boehringer Ingelheim | 26 | $579 |
| Biohaven Pharmaceutical Holding Company Ltd. | 15 | $470 |
| AbbVie | 21 | $424 |
| GSK | 21 | $381 |
| Intra-sana Laboratories | 4 | $372 |
| Biohaven Pharmaceuticals, Inc. | 11 | $353 |
| Novo Nordisk | 22 | $339 |
| Amarin Pharma, Inc. | 19 | $325 |
| AstraZeneca | 18 | $253 |
| Lilly USA, LLC | 13 | $240 |
| Takeda Pharmaceuticals U.S.A., Inc. | 9 | $190 |
| Almatica Pharma LLC | 7 | $155 |
| Kowa Pharmaceuticals America, Inc. | 8 | $120 |
| Daiichi Sankyo Inc. | 6 | $119 |
| Bayer | 4 | $109 |
| Idorsia Pharmaceuticals US Inc | 6 | $103 |
| Pfizer | 5 | $79 |
| Currax Pharmaceuticals LLC | 5 | $77 |
| Ascensia Diabetes Care US Inc. | 2 | $64 |
| Merck | 3 | $59 |
| Novartis | 3 | $50 |
| Dexcom, Inc. | 2 | $40 |
| Boston Scientific | 1 | $38 |
| Johnson & Johnson | 2 | $38 |
| Shield Therapeutics Inc | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Exact Sciences | 1 | $23 |
| Amneal Pharmaceuticals LLC | 1 | $22 |
| Nevro Corp. | 1 | $21 |
| Lundbeck LLC | 1 | $20 |
| Evofem Biosciences, Inc. | 1 | $20 |
| Metacel Pharmaceuticals LLC | 1 | $19 |
| Bausch Health US, LLC | 1 | $19 |
| Clarus Therapeutics Inc. | 1 | $17 |
| Phadia US Inc. | 1 | $16 |
| Incyte Corporation | 1 | $15 |
| Vistapharm, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- NURTEC ODT$357
- Reltone 200 Mg$311
- Reltone 400 Mg$311
- KRYSTEXXA$243
- JARDIANCE$125
- GLYCATE$111
How this compares
$5,937 in reported general payments places this provider in the 90th percentile of 573 medical providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PaxlovidNirmatrelvir/Ritonavir | 15 | $1,429 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 17 | $997 |
| Levothyroxine Sodium | 32 | $517 |
| Rosuvastatin Calcium | 20 | $383 |
| Amlodipine Besylate | 44 | $326 |
| Olmesartan Medoxomil | 11 | $326 |
| Azelastine Hcl | 21 | $325 |
| Fluticasone Propionate | 14 | $261 |
| Atorvastatin Calcium | 38 | $245 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 31 | $233 |
| Losartan Potassium | 24 | $202 |
| Famotidine | 19 | $197 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 12 | $183 |
| Doxycycline Hyclate | 26 | $171 |
| Sertraline Hcl | 22 | $167 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPaxlovid | $79 | $1,42915 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $22 | $51732 claims |
| Almatica Pharma LLCSertraline Hcl | $155 | $16722 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 573 medical providers in New Jersey.
Other medical in Florham Park
- Shannon WelnerVerona$176K
- Christinna DelgenioColts Neck$114K
- Anita FoxVerona$17K
- Therese CasasKinnelon$16K
- Joseph CollettiLinwood$16K
- Melissa MiaoKearny$14K
- Gabriela Plesek-AndiaVerona$13K
- Stephanie PhillipsMarlton$12K
- Sean AdairCape May Court House$12K
- Shane CourtneyLinwood$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.